Literature DB >> 22626600

Allergen immunotherapy practice patterns: a worldwide survey.

Punita Ponda1, Sima Mithani, Yelena Kopyltsova, Cristina Sison, Payel Gupta, Désirée Larenas, Vincent R Bonagura.   

Abstract

BACKGROUND: Allergists around the world have different practice styles when administering subcutaneous aeroallergen immunotherapy (IT) in peak pollen seasons, especially when changing doses or frequency of IT. The Immunotherapy practice parameters do not specifically address this issue.
OBJECTIVE: Given the paucity of good data about adjustment of allergen immunotherapy during the pollen seasons, we examined whether a significant difference is present in the way allergists administer immunotherapy during allergy seasons.
METHODS: To quantify the practice styles of allergists who are members of the American Academy of Allergy, Asthma and Immunology (AAAAI), a self-reported electronic survey was disseminated in September 2010 with the help of the AAAAI Needs Assessment Committee. The responses were tallied and analyzed according to demographic information.
RESULTS: A total of 1,201 allergists in the AAAAI responded to the survey. Most responders practice in an urban or suburban nonacademic practice in the United States and have been in practice for more than 10 years. The size of their practice was variable. Those in practice for more than 10 years were more likely to adjust the dose and frequency of immunotherapy in pollen seasons.
CONCLUSION: This survey highlights the differences in the practice styles of AAAAI member allergists, and these differences may be associated with their demographic characteristics. Given the wide variability in how allergists adjust dose and frequency of immunotherapy during pollen seasons, establishing guidelines regarding this routine dilemma might help standardize the delivery of treatment to patients.
Copyright © 2012 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22626600     DOI: 10.1016/j.anai.2012.04.002

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  2 in total

Review 1.  Immunotherapy safety: what have we learned from surveillance surveys?

Authors:  Jennifer A Kannan; Tolly G Epstein
Journal:  Curr Allergy Asthma Rep       Date:  2013-08       Impact factor: 4.806

Review 2.  Use of new technology to improve utilization and adherence to immunotherapy.

Authors:  Smita Joshi; Ves Dimov
Journal:  World Allergy Organ J       Date:  2014-11-21       Impact factor: 4.084

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.